PTGX NASDAQ
Protagonist Therapeutics, Inc.
1W: -1.3%
1M: -4.1%
3M: +6.5%
YTD: +60.7%
1Y: +118.8%
3Y: +697.1%
5Y: +644.6%
$140.06
+0.87 (+0.63%)
Weekly Expected Move ±3.7%
$130
$135
$140
$145
$151
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2021-07-28
Earliest Filing
2024-11-18
Latest Filing
partner: 4
Counterparties (Filed by PTGX)
4 relationshipsCompanies named in PTGX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | — | partner | Amendment to License and Collaboration Agreement regarding milestone payments | 2024-11-18 | View |
| Takeda Pharmaceuticals USA, Inc. | TKPHF | partner | License and Collaboration Agreement for development and commercialization of rusfertide | 2024-01-31 | View |
| Zealand Pharma A/S | ZLDPF | partner | Former collaborator and current counterparty in arbitration resolution regarding royalty and milestone payments for rusf | 2021-08-10 | View |
| Janssen Biotech, Inc. | — | partner | Amended and restated License and Collaboration Agreement for IL-23 receptor antagonist drug candidates | 2021-07-28 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-18 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-26 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-20 | Other Events | View | |
| 2025-03-11 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-21 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-06 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-11-18 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-20 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-26 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR